home / stock / mrtx / mrtx articles
Editor's note: The headline of this story has been updated to make clearer the FDA vote is on late-stage Lumakras data. FDA advisers conc...
Editor's note: The headline of this story has been updated to make clearer the FDA vote is on late-stage Lumakras data. FDA advisers conc...
Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday. Several analysts updated their price targets on the stock, and investors...
Jamie Christensen, EVP & Chief Scientific Officer at Mirati Therapeutics (NASDAQ:MRTX), reported a large insider sell on September 12, accordin...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...